

**IN THE CLAIMS:**

Amend the claims as follows:

Claims 1-10. (Canceled)

11. (Currently Amended) A method for detecting differentiation from a hematopoietic stem cell into a monocyte and/or a macrophage, which comprises ~~using a substance having binding activity to~~ contacting a specimen derived from cells or tissues of a person to be tested with an antibody against a human VEGF receptor Flt-1 to thereby detect a monocyte and/or a macrophage in the specimen.

Claim 12. (Canceled)

13. (Currently Amended) The method according to claim ~~12~~11, wherein the antibody against a human VEGF receptor Flt-1 is a polyclonal antibody or a monoclonal antibody.

14. (Currently Amended) The method according to claim 13, wherein the monoclonal antibody is an antibody selected from the group consisting of an antibody produced by a hybridoma, a humanized antibody and antibody fragments thereof.

15. (Currently Amended) The method according to claim 14, wherein the antibody produced by a hybridoma is an antibody selected from the group consisting of

an antibody produced by hybridoma KM1730 (FERM BP-5697), an antibody produced by hybridoma KM1731 (FERM BP-5718), an antibody produced by hybridoma KM1732 (FERM BP-5698), an antibody produced by hybridoma KM1748 (FERM BP-5699) and an antibody produced by hybridoma KM1750 (FERM BP-5700).

16. (Currently Amended) The method according to claim 14, wherein the humanized antibody is an antibody selected from the group consisting of a human chimeric antibody and a human complementarity determining region-grafted antibody.

17. (Currently Amended) The method according to claim 16, wherein the human chimeric antibody is ~~KM2532 or KM2550~~ an antibody selected from the group consisting of:

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1732HA2 (FERM BP-6354) and the L chain variable region DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1732L2-1 (FERM BP-6352), and  
an antibody comprising the H chain variable region DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1750H2-1 (FERM BP-6353) and the L chain variable region DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1750L3-1 (FERM BP-6355).

18. (Currently Amended) The method according to claim 16, wherein the human complementarity determining region-grafted antibody is an antibody selected from the group consisting of: ~~KM8550, KM8551, KM8552, KM8553, KM8554 and KM8555~~

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(I) (FERM BP-6716),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(IV) (FERM BP-6717),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(I) (FERM BP-6716),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(IV) (FERM BP-6717),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /phKM1750LV4 (FERM BP-6718), and

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /pHKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* DH5 $\alpha$ /phKM1750LV4 (FERM BP-6718).

19. (Original) The method according to claim 14, wherein the antibody fragment is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, a single chain antibody, a disulfide-stabilized Fv and a peptide comprising a complementarity determining region.

20. (Currently Amended) The method according to claim ~~12~~11, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

Claims 21-65. (Canceled)

66. (New) The method according to claim 11, wherein the cells or tissues are derived from blood.